Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 273-227-8 | CAS number: 68953-84-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP study consistent with OECD guidelines
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 995
- Report date:
- 1995
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- At the time of testing, the LLNA method (OECD 429) was not yet available as OECD adopted guideline.
Test material
- Reference substance name:
- 1,4-Benzenediamine, N,N'-mixed Ph and tolyl derivs.
- EC Number:
- 273-227-8
- EC Name:
- 1,4-Benzenediamine, N,N'-mixed Ph and tolyl derivs.
- Cas Number:
- 68953-84-4
- Molecular formula:
- C18-20H16-20N2
- IUPAC Name:
- Reaction mass of N-phenyl,N'-o-tolyl-phenylene diamine, N,N'-diphenyl-p-phenylene diamine and N,N'-di-o-tolyl-phenylene diamine
Constituent 1
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- Hartley
- Sex:
- male/female
- Details on test animals and environmental conditions:
- Animals were obtained from Harlan Sprague Dawley, Michigan. They were young adults of both sexes with study initiation body weights of 350 - 500 g. The test animals were housed individually, and fed Purina Guinea Pig chow ad libitum. Drinking water also available ad libitum. The animals were quarantined for minimum of 5 days prior to study initiation. Animal rooms were 65 - 75 degrees F, and humidity 36-63% with 12 hr light/12 hr dark photocycle. Ventilation was 10-12 room air changes per hr.
Study design: in vivo (non-LLNA)
Inductionopen allclose all
- Route:
- intradermal
- Vehicle:
- other: Induction - acetone/propylene glycol (0.5% v/v)
- Concentration / amount:
- Induction - 5% test substance in acetone/propylene glycol soln
Challenge - Either 100% of test substance or a 25% solutionn of test substance in acetone/mineral oil.
Challengeopen allclose all
- Route:
- epicutaneous, semiocclusive
- Vehicle:
- other: Induction - acetone/propylene glycol (0.5% v/v)
- Concentration / amount:
- Induction - 5% test substance in acetone/propylene glycol soln
Challenge - Either 100% of test substance or a 25% solutionn of test substance in acetone/mineral oil.
- No. of animals per dose:
- 20 animals were used in each of the two challenge test groups (25% & 100% DAPD)
- Details on study design:
- Range finding tests showed that application of up to and including 100% test chemical in a Hilltop chamber did not cause significant irritation, and thus was acceptable for use in induction & challenge phases. For intradermal assessments, injected soln concentration up to & including 5% was also without significant signs of irritation.
In the main study, induction exposures to test groups on Day 0 consisted of intradermal injections (at 2 opposing dorsal skin sites) of Freund's adjuvant, 5% test chemical in acetone/propylene glycol, and test chemical in Freund's adjuvant. Topical exposures were performed on Day 7 when sodium lauryl sulfate was applied to defat skin sites prior to application of 100% test chemical (0.35 g) 24 hr later. This chemical exposure was 48 hr in duration. Both induction exposures were done on single occasions. 20 guinea pigs (10 of each sex) were in this test group.
Control groups were established with 10 animals (5M/5F). These guinea pigs were treated with the Freund's adjuvant and solvents as employed in the test group above.
The challenge exposures were performed on Day 21. The chemical test group was exposed to 25 or 100% test chemical by applying it to the right side of each animal under a semi-occlusive patch or in a chamber, respectively. The chemical was kept in dermal contact for 24 hrs at which time, the site was wiped clean. These dermal sites were then scored 24 & 48 hrs later for signs of irritation (allergic responses).
A rechallenge was performed on Day 28 of the study. Dosing and skin scoring was as that described above for the initial challenge exposure. - Challenge controls:
- Challenge controls were given identical test chemical exposures on Days 21 and 28 as described above for test groups.
- Positive control substance(s):
- yes
- Remarks:
- Dichloronitrobenzene
Results and discussion
- Positive control results:
- DNCB results conducted in 6 guinea pigs on Day 21 showed significant skin irritating responses. Irritation scores were 2.5/4.0 & 2.5/4.0 for 24 & 48 hr readings. Controls (4 animals) had irritation scores of 0.5 & 0.3/4.0 for 24 & 48 hrs, respectively. These data indicated assay responsiveness to exposures to allergenic chemicals.
In vivo (non-LLNA)
Resultsopen allclose all
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 25%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- no signs
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 25%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: no signs.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 25%
- No. with + reactions:
- 5
- Total no. in group:
- 20
- Clinical observations:
- 5 with edema
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 25%. No with. + reactions: 5.0. Total no. in groups: 20.0. Clinical observations: 5 with edema.
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 25%
- No. with + reactions:
- 3
- Total no. in group:
- 20
- Clinical observations:
- 1 with edema, 2 with desquamation
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 48.0. Group: test group. Dose level: 25%. No with. + reactions: 3.0. Total no. in groups: 20.0. Clinical observations: 1 with edema, 2 with desquamation.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 100%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- no signs
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 100%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: no signs.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 100%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- no signs
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 100%. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: no signs.
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 100%
- No. with + reactions:
- 5
- Total no. in group:
- 20
- Clinical observations:
- 5 with desquamation
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 48.0. Group: test group. Dose level: 100%. No with. + reactions: 5.0. Total no. in groups: 20.0. Clinical observations: 5 with desquamation.
- Reading:
- rechallenge
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 25%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- no signs
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 24.0. Group: negative control. Dose level: 25%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: no signs.
- Reading:
- rechallenge
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 25%
- No. with + reactions:
- 15
- Total no. in group:
- 20
- Clinical observations:
- 1 desquamation, 15 edema, 6 blanching
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 24.0. Group: test group. Dose level: 25%. No with. + reactions: 15.0. Total no. in groups: 20.0. Clinical observations: 1 desquamation, 15 edema, 6 blanching.
- Reading:
- rechallenge
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 25%
- No. with + reactions:
- 11
- Total no. in group:
- 20
- Clinical observations:
- 11 desquamation, 10 edema, 6 blanching
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 48.0. Group: test group. Dose level: 25%. No with. + reactions: 11.0. Total no. in groups: 20.0. Clinical observations: 11 desquamation, 10 edema, 6 blanching.
- Reading:
- rechallenge
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 100%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- no signs
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 24.0. Group: negative control. Dose level: 100%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: no signs.
- Reading:
- rechallenge
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 100%
- No. with + reactions:
- 15
- Total no. in group:
- 20
- Clinical observations:
- 8 desquamation, 15 edema, 13 blanching
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 24.0. Group: test group. Dose level: 100%. No with. + reactions: 15.0. Total no. in groups: 20.0. Clinical observations: 8 desquamation, 15 edema, 13 blanching.
- Reading:
- rechallenge
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 100%
- No. with + reactions:
- 15
- Total no. in group:
- 20
- Clinical observations:
- 14 desquamation, 14 edema, 9 blanching
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 48.0. Group: test group. Dose level: 100%. No with. + reactions: 15.0. Total no. in groups: 20.0. Clinical observations: 14 desquamation, 14 edema, 9 blanching.
Applicant's summary and conclusion
- Interpretation of results:
- sensitising
- Remarks:
- Migrated information
- Conclusions:
- The results in guinea pigs show the chemical to have sensitization activity in dermal tests in guinea pigs.
- Executive summary:
Test material was subjected to a guinea pig maximization sensitization assay according to OECD and GLP guidelines. The induction phase included both intradermal and epidermal exposures to test chemical plus adjuvant.
The dermal response following 48h after the first challenge to 25% or 100% of chemical resulted in clinical effects (edema or desquamation) for 15% or 25% of test animals, respectively.
48 Hours after the second challenge 55% of the animals exposed to 25% of test chemical showed signs of desquamation, edema or blanching. In the test group exposed to 100% of test chemical, 75% of the animals showed signs of a sensitization reaction after 48 hours.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
Questo sito web si avvale di cookie affinché possiate usufruire della migliore esperienza sui nostri siti web.